FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Rosenblum Mark J

 2. Date of Event Requiring Statement (MM/DD/YYYY)
9/10/2019 

 3. Issuer Name and Ticker or Trading Symbol

Salarius Pharmaceuticals, Inc. [SLRX]

(Last)        (First)        (Middle)

C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOMBE BLVD., SUITE J - 608

 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Exec VP Finance, Interim CFO /

(Street)

HOUSTON, TX 77021      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)

9/10/2019 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)  (1)9/10/2029 Common Stock 19008.0 $8.0 D  
Explanation of Responses:
(1) These options have a 4-year vesting schedule with 25% vesting on September 30, 2020 and 1/12th of the balance vesting on the last day of each calendar quarter thereafter.

Remarks:
Exhibit List: Exhibit 24 - Power of Attorney
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Rosenblum Mark J
C/O SALARIUS PHARMACEUTICALS, INC.
2450 HOLCOMBE BLVD., SUITE J - 608
HOUSTON, TX 77021

Exec VP Finance, Interim CFO
Signatures
/s/ Mark J. Rosenblum9/12/2019
**Signature of Reporting PersonDate
FLEX PHARMA, INC. (NASDAQ:FLKS)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos FLEX PHARMA, INC..
FLEX PHARMA, INC. (NASDAQ:FLKS)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos FLEX PHARMA, INC..